US molecular biology specialist Qiagen has co-led a $27m series B round of funding for Exosome Diagnostics, a US developer of fluid-based molecular diagnostics.
Exosome Diagnostics, a US developer of fluid-based molecular diagnostics, has raised $27m in a series B funding round co-led by strategic investor Qiagen and life sciences private equity investor, Arcus Ventures.
Other investors in this round included new backers Tiger Partner, CD Ventures, Monashee Capital, b-to-v Partners and return investors NGN Capital and Forbion Capital Partners. The company has raised a reported $47m to date.
Proceeds will be used to advance development of Exosmome’s proprietary platform technology and commercial programmes…
